Financial Ratios Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.24 USD | +5.76% |
|
-5.98% | +46.30% |
| 06-29 | Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark | CI |
| 06-29 | Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index | CI |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -21.92 | -19.82 | -27.72 | -13.66 | -7.64 | ||
Return on Total Capital | -24.85 | -21.1 | -32.95 | -20.65 | -12.6 | ||
Return On Equity % | -40.35 | -35.06 | -60.07 | -36.15 | -16.94 | ||
Return on Common Equity | -49.51 | -35.06 | -60.07 | -36.15 | -16.94 | ||
Margin Analysis | |||||||
Gross Profit Margin % | - | - | - | -49.25 | -8.11 | ||
SG&A Margin | - | - | - | 58.01 | 35.72 | ||
EBITDA Margin % | - | - | - | -96.52 | -37.08 | ||
EBITA Margin % | - | - | - | -107.26 | -43.83 | ||
EBIT Margin % | - | - | - | -107.26 | -43.83 | ||
Income From Continuing Operations Margin % | - | - | - | -96.14 | -31.23 | ||
Net Income Margin % | - | - | - | -96.14 | -31.23 | ||
Net Avail. For Common Margin % | - | - | - | -96.14 | -31.23 | ||
Normalized Net Income Margin | - | - | - | -57.96 | -20.1 | ||
Levered Free Cash Flow Margin | - | - | - | 108.4 | -91.42 | ||
Unlevered Free Cash Flow Margin | - | - | - | 108.4 | -91.42 | ||
Asset Turnover | |||||||
Asset Turnover | - | - | - | 0.2 | 0.28 | ||
Fixed Assets Turnover | - | - | - | 1.27 | 2.32 | ||
Short Term Liquidity | |||||||
Current Ratio | 20.96 | 10.79 | 5.07 | 2.4 | 6.12 | ||
Quick Ratio | 20.8 | 10.58 | 5 | 2.37 | 6.05 | ||
Operating Cash Flow to Current Liabilities | -3.57 | -3.62 | -0.94 | 0.27 | -0.36 | ||
Average Days Payable Outstanding | - | - | - | 46 | 28.34 | ||
Long Term Solvency | |||||||
Total Debt/Equity | - | 17.32 | 25.68 | 19.16 | 16.82 | ||
Total Debt / Total Capital | - | 14.76 | 20.44 | 16.08 | 14.4 | ||
LT Debt/Equity | - | 16.16 | 23.92 | 17.49 | 14.93 | ||
Long-Term Debt / Total Capital | - | 13.78 | 19.03 | 14.68 | 12.78 | ||
Total Liabilities / Total Assets | 5.14 | 20.73 | 40.99 | 49.19 | 48.05 | ||
EBIT / Interest Expense | - | - | - | - | - | ||
EBITDA / Interest Expense | - | - | - | - | - | ||
(EBITDA - Capex) / Interest Expense | - | - | - | - | - | ||
Total Debt / EBITDA | - | -0.47 | -0.36 | -0.68 | -1.07 | ||
Net Debt / EBITDA | 4.89 | 2.16 | 1.46 | 5.27 | 9.22 | ||
Total Debt / (EBITDA - Capex) | - | -0.42 | -0.31 | -0.64 | -0.95 | ||
Net Debt / (EBITDA - Capex) | 4.3 | 1.91 | 1.27 | 4.95 | 8.18 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | - | - | - | - | 63.54 | ||
Gross Profit, 1 Yr. Growth % | - | - | - | -63.97 | -73.07 | ||
EBITDA, 1 Yr. Growth % | 157.53 | 53.55 | 26.19 | -46.76 | -37.18 | ||
EBITA, 1 Yr. Growth % | 160.2 | 54.2 | 27.52 | -43.4 | -33.17 | ||
EBIT, 1 Yr. Growth % | 160.2 | 54.2 | 27.52 | -43.4 | -33.17 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 106.13 | 46.71 | 24.75 | -46.29 | -46.87 | ||
Net Income, 1 Yr. Growth % | 106.13 | 46.71 | 24.75 | -46.29 | -46.87 | ||
Normalized Net Income, 1 Yr. Growth % | 106.13 | 46.85 | 24.21 | -48.02 | -43.27 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | -87.49 | -22.34 | 14.63 | -62.65 | -52.73 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 166.6 | 402.29 | 1.14 | -10.06 | -10.55 | ||
Total Assets, 1 Yr. Growth % | 641.89 | -6.54 | -11.28 | 44.44 | 2.26 | ||
Tangible Book Value, 1 Yr. Growth % | -813.17 | -21.9 | -33.96 | 24.37 | 4.54 | ||
Common Equity, 1 Yr. Growth % | -813.17 | -21.9 | -33.96 | 24.37 | 4.54 | ||
Cash From Operations, 1 Yr. Growth % | 157.51 | 55.76 | -52.63 | -195.88 | -154.29 | ||
Capital Expenditures, 1 Yr. Growth % | 187.16 | 32.67 | 47.48 | -79.06 | 17.85 | ||
Levered Free Cash Flow, 1 Yr. Growth % | -906.38 | 18.13 | -23.39 | -253.59 | -237.93 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | -906.38 | 18.13 | -23.39 | -253.59 | -237.93 | ||
Compound Annual Growth Rate Over Two Years | |||||||
Gross Profit, 2 Yr. CAGR % | - | - | - | - | -68.85 | ||
EBITDA, 2 Yr. CAGR % | -13.73 | 98.86 | 39.2 | -18.03 | -42.17 | ||
EBITA, 2 Yr. CAGR % | -12.84 | 100.31 | 40.23 | -15.04 | -38.5 | ||
EBIT, 2 Yr. CAGR % | -12.84 | 100.31 | 40.23 | -15.04 | -38.5 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | -10.77 | 73.9 | 35.28 | -18.14 | -46.58 | ||
Net Income, 2 Yr. CAGR % | -10.77 | 73.9 | 35.28 | -18.14 | -46.58 | ||
Normalized Net Income, 2 Yr. CAGR % | -10.77 | 73.99 | 35.06 | -19.64 | -45.7 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | -78.76 | -68.83 | -5.65 | -34.57 | -57.98 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 203.85 | 265.94 | 125.39 | -4.62 | -10.3 | ||
Total Assets, 2 Yr. CAGR % | 474.63 | 163.33 | -8.94 | 13.2 | 21.53 | ||
Tangible Book Value, 2 Yr. CAGR % | 434.85 | 136.01 | -28.18 | -9.37 | 14.03 | ||
Common Equity, 2 Yr. CAGR % | 434.85 | 136.01 | -28.18 | -9.37 | 14.03 | ||
Cash From Operations, 2 Yr. CAGR % | -10.48 | 100.28 | -14.1 | -32.61 | -27.86 | ||
Capital Expenditures, 2 Yr. CAGR % | -23.48 | 95.18 | 39.88 | -44.42 | -50.32 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 208.64 | -4.87 | 6.4 | 45.55 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 208.64 | -4.87 | 6.4 | 45.55 | ||
Compound Annual Growth Rate Over Three Years | |||||||
EBITDA, 3 Yr. CAGR % | - | 4.55 | 70.88 | 1.04 | -24.99 | ||
EBITA, 3 Yr. CAGR % | - | 5.42 | 72.31 | 3.63 | -21.58 | ||
EBIT, 3 Yr. CAGR % | - | 5.42 | 72.31 | 3.63 | -21.58 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 5.32 | 55.67 | -0.57 | -29.13 | ||
Net Income, 3 Yr. CAGR % | - | 5.32 | 55.67 | -0.57 | -29.13 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 5.35 | 55.5 | -1.76 | -28.45 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | -67.28 | -51.89 | -30.72 | -41.29 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 259.27 | 138.36 | 65.94 | -6.64 | ||
Total Assets, 3 Yr. CAGR % | - | 213.67 | 83.23 | 6.2 | 9.43 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 181.65 | 54.37 | -13.75 | -4.95 | ||
Common Equity, 3 Yr. CAGR % | - | 181.65 | 54.37 | -13.75 | -4.95 | ||
Cash From Operations, 3 Yr. CAGR % | - | 7.67 | 23.86 | -10.9 | -37.29 | ||
Capital Expenditures, 3 Yr. CAGR % | - | -8.07 | 77.78 | -25.72 | -28.6 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 93.97 | 10.18 | 16.02 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 93.97 | 10.18 | 16.02 | ||
Compound Annual Growth Rate Over Five Years | |||||||
EBITDA, 5 Yr. CAGR % | - | - | - | -5.15 | 10.79 | ||
EBITA, 5 Yr. CAGR % | - | - | - | -3.3 | 14.12 | ||
EBIT, 5 Yr. CAGR % | - | - | - | -3.3 | 14.12 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | -4.78 | 1.49 | ||
Net Income, 5 Yr. CAGR % | - | - | - | -4.78 | 1.49 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | -5.46 | 2.09 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | -56.83 | -54.43 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 111.36 | 61.23 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 108.65 | 55.48 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 78.95 | 36.75 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 78.95 | 36.75 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | -10.73 | -0.22 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | -24.83 | 6.76 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 71.59 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 71.59 |
- Stock Market
- Stocks
- GLUE Stock
- Financials Monte Rosa Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















